IRON DISC MEDICINE INC

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 2:30 p.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit

Media Contact

Peg Rusconi

Verge Scientific Communications

Investor Relations Contact

Suzanne Messere

Stern Investor Relations



EN
21/04/2023

Underlying

IRONDISC MEDICINE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DISC MEDICINE INC

 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd at 9:50 a.m. ET in Boston, MA.Leerink Global Healthcare Conference on Monday, March 9th at 3:40 p.m. ET in...

2h / 35m 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Receives Complete Response Letter from FDA for Bitoperti...

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyriaFDA indicated a need to see the results of the ongoing Phase 3 APOLLO study before making a decisionOngoing Phase 3 APOLLO study potential to serve as basis for traditional approval; topline data anticipated Q4 2026 WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWI...

February 13, 2026 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources ...

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company’s Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple commercial...

January 12, 2026 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Highlights Recent Achievements and Key Business Objectiv...

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed by an End of Phase 2 MeetingInitial data from the ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and Phase 1b study in sickle cell disease (SCD) expected in H2 2026 WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (...

January 12, 2026 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Con...

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th at 3:00 pm PT / 6:00 pm ET. A live webcast of ...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch